- Home
- CUE vs LSBK Comparison
CUE vs LSBK Comparison
Compare CUE & LSBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUE
- LSBK
- Stock Information
- Founded
- CUE 2014
- LSBK 1891
- Country
- CUE United States
- LSBK United States
- Employees
- CUE N/A
- LSBK N/A
- Industry
- CUE Biotechnology: Pharmaceutical Preparations
- LSBK Savings Institutions
- Sector
- CUE Health Care
- LSBK Finance
- Exchange
- CUE Nasdaq
- LSBK Nasdaq
- Market Cap
- CUE 59.5M
- LSBK 90.0M
- IPO Year
- CUE 2018
- LSBK 2006
- Fundamental
- Price
- CUE $0.77
- LSBK $13.06
- Analyst Decision
- CUE Strong Buy
- LSBK
- Analyst Count
- CUE 2
- LSBK 0
- Target Price
- CUE $3.00
- LSBK N/A
- AVG Volume (30 Days)
- CUE 127.4K
- LSBK 30.9K
- Earning Date
- CUE 11-13-2025
- LSBK 10-22-2025
- Dividend Yield
- CUE N/A
- LSBK 2.76%
- EPS Growth
- CUE N/A
- LSBK 39.59
- EPS
- CUE N/A
- LSBK 1.05
- Revenue
- CUE $8,286,000.00
- LSBK $26,488,000.00
- Revenue This Year
- CUE N/A
- LSBK N/A
- Revenue Next Year
- CUE $10.19
- LSBK N/A
- P/E Ratio
- CUE N/A
- LSBK $12.41
- Revenue Growth
- CUE N/A
- LSBK 1.75
- 52 Week Low
- CUE $0.45
- LSBK $11.50
- 52 Week High
- CUE $1.99
- LSBK $13.48
- Technical
- Relative Strength Index (RSI)
- CUE 51.01
- LSBK 57.34
- Support Level
- CUE N/A
- LSBK $12.85
- Resistance Level
- CUE $0.79
- LSBK $13.26
- Average True Range (ATR)
- CUE 0.03
- LSBK 0.19
- MACD
- CUE -0.03
- LSBK -0.06
- Stochastic Oscillator
- CUE 91.08
- LSBK 33.33
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
About LSBK Lake Shore Bancorp Inc.
Lake Shore Bancorp Inc operates as a savings and loan holdings company. The bank's business consists of attracting retail deposits from the general public in the areas surrounding its branch offices and investing those deposits, together with funds generated from operations, in commercial real estate loans, one-to-four family residential mortgage loans, home equity lines of credit and to a lesser extent, commercial business loans, consumer loans, and investment securities. Its revenues are principally derived from interest earned on loans and investment securities.